Charlie is an international research group, looking for better and more effective treatment for patients with PDE and GA1.
CHARLIE is a research project for lysine metabolism disorders. Examples of these disorders are Pyridoxine-dependent Epilepsy (PDE) and Glutaric Aciduria type 1 (GA1). Without treatment, patients with these disorders often get serious neurological complaints and need continuous care. However, the available treatment does not relief all symptoms. And the diet that needs to be followed is often burdensome and has a major impact on the patients’ quality of life.
In the CHARLIE project, physicians and patients collaborate on research into better treatment. Physicians are going to investigate how damage to the brain can be prevented, if at all. And they may investigate new ways for developing gene therapy for GA1. Patients will indicate which treatment they receive and what does and does not go well. What do they miss in their treatment and the support they receive? What can be improved and how? What should be taken into account if a new treatment is being developed and subsequently becomes available? By investigating these issues, the effect of therapy can be identified for each patient and treatment can be tailored individually.